CEL-SCI (CVM -0.7%) announces that its Phase 3 clinical trial
evaluating immunotherapy Multikine (leukocyte interleukin injection) in
head and neck cancer patients has reached the fatality threshold (298
deaths) allowing for database lock and final analysis to be completed.
The primary endpoint is overall survival at year 3
compared to standard-of-care surgical resection followed by radiation
therapy or radiochemotherapy.
https://seekingalpha.com/news/3568256-cel-sci-almost-late-stage-multikine-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.